Prolyl Hydroxylase Inhibition Mitigates Pouchitis

Area of Science:

• Gastroenterology
• Molecular Biology
• Inflammation Research

Background:

• Pouchitis is a common complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) or familial adenomatous polyposis (FAP).
• Hypoxia-inducible transcription factor prolyl hydroxylase-containing enzymes (PHDs) are oxygen sensors involved in adaptive gene expression and are emerging therapeutic targets in intestinal inflammation.
• Pharmacological inhibition of PHDs has not been validated for pouchitis treatment.

Purpose of the Study:

• To investigate the role of PHD1, PHD2, and PHD3 in pouchitis.
• To evaluate the therapeutic potential of pan-PHD inhibition using dimethyloxalylglycine (DMOG) in a preclinical model of pouchitis.

Main Methods:

• PHD1-3 mRNA and protein expression were analyzed in patient biopsies from IPAA surgery for UC and FAP.
• A rat model of dextran sulfate sodium (DSS)-induced pouchitis after IPAA was established.
• The effect of DMOG on clinical and molecular parameters of pouchitis was assessed.

Main Results:

• PHD1 was overexpressed in pouchitis biopsies from UC patients, correlating with disease activity, unlike PHD2 and PHD3.
• DMOG treatment significantly reduced DSS-induced pouchitis in the rat IPAA model.
• DMOG restored intestinal epithelial barrier function by upregulating tight junction proteins and reducing apoptosis, thereby attenuating inflammation.

Conclusions:

• PHD1 is upregulated in pouchitis associated with IPAA for UC.
• Targeting PHD1 with small-molecule inhibitors represents a promising therapeutic strategy for pouchitis.
• These findings provide a strong rationale for developing PHD1 inhibitors for pouchitis treatment in UC patients.